血清CA15-3、CEA检测联合全身骨显像在乳腺癌骨转移中的诊断价值

目的 评价血清肿瘤标志物糖类抗原15-3(CA15-3)、癌胚抗原(CEA)检测联合全身骨显像在乳腺癌骨转移诊断中的价值.方法 对97例乳腺癌患者(其中,骨转移组46例、无骨转移组51例)及45例良性乳腺疾病患者(良性病变组)行SPECT全身骨显像,对骨显像阴性但骨痛明显患者,再行CT或MRI检查以确诊.同时,用电化学...     

肺癌18F-FLT PET和18F-FDG PET的临床对比研究

目的 探讨18F-FLT PET在肺癌诊断和肿瘤增殖检测方面的应用价值.方法 对2005年9月-2008年10月解放军总医院收治的36例(男27例,女9例,年龄38～74岁)胸部CT疑似肺癌患者进行18F-FLT PET扫描,对同期收治的42例(男29例,女13例,年龄37～75岁)胸部CT疑似肺癌患者进行18F-FD...     

Predictability and Inducibility of Detachment of Prostatic Central Gland Tissue after Prostatic Artery Embolization: Post Hoc Analysis of a Randomized Controlled Trial

Purpose

To assess the frequency and potential predictors of prostatic central gland tissue detachment (CGD), an enucleation-like reaction that sporadically occurred in a randomized controlled trial assessing efficacy and safety of prostatic artery embolization (PAE).

Prostatic Artery Embolization with 250-μm Spherical Polyzene-Coated Hydrogel Microspheres for Lower Urinary Tract Symptoms with Follow-up MR Imaging

Purpose

To evaluate clinical outcomes and possible MR imaging predictors of clinical success after prostatic artery embolization (PAE) with 250-μm hydrogel particles.

Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy

PurposeTo identify patients at extremely low risk of biochemical recurrence (BCR) of prostate cancer after low-dose-rate brachytherapy (LDR-BT) to determine when prostate-specific antigen (PSA) monitoring can be stopped.Methods and MaterialsWe retrospectively reviewed clinicopathologic data of patients with prostate cancer who underwent LDR-BT between 2003 and 2011. Of 1569 patients reviewed, 689 (43.9%) received combination external beam radiotherapy, and 970 (61.8%) had neoadjuvant hormonal therapy. We stratified patients according to risk factors identified by multivariate analysis and assessed the factors for an association with BCR (defined as ≥2 ng/mL higher than the nadir).ResultsThe median followup was 96 months. Of 1531 patients who were BCR-free at 3 years after treatment, 76 subsequently developed BCR; of 1500 who were BCR-free at 5 years, 45 eventually had BCR. On multivariate analysis, independent risk factors for BCR were the National Comprehensive Cancer Network risk group at diagnosis and PSA levels at 3 or 5 years after radiotherapy. In the low-risk group, no patient with a PSA level ≤0.2 ng/mL at 3 years after radiotherapy subsequently developed BCR. In the intermediate-risk group, no patients with a PSA level ≤0.2 ng/mL at 5 years subsequently developed BCR.ConclusionsThe National Comprehensive Cancer Network risk group at diagnosis and PSA values at 3 and 5 years after LDR-BT are independently associated with a risk of later BCR. Using these two factors may help to select patients for whom PSA monitoring could be stopped because they have an extremely low risk of later BCR.     

诱导骨髓间充质干细胞再生汗腺组织的神经与血管支配研究

目的研究诱导骨髓间充质干细胞再生汗腺组织后的神经与血管分布特征,以确认再生汗腺组织是否受到新生神经的支配和新生血管的血液供应,进而评价再生汗腺组织的质量。方法选择烧伤后行瘢痕切除术患者4例。每例患者均设创面自体骨髓间充质干细胞（MSCs）移植和对照两个部位。移植部位在瘢痕切除的创面上接种经过诱导的MSCs,而对照部位除未接种MSCs外,其余方法同治疗创面。术后3个月在移植部位和对照部位分别进行发汗试验。在移植部位发汗试验呈阳性处取材,同时取对照部位的组织和术中切下的瘢痕组织。采用免疫组织化学二步法检测所取组织标本的S-100蛋白（S-100）、神经元特异性烯醇化酶（NSE）、八因子相关抗原（Ⅷ－RAg）和CD34的表达,并与正常皮肤作比较研究。结果4例创面移植部位发汗试验均呈阳性,对照部位发汗试验阴性。免疫组织化学检测显示移植部位的真皮浅层有结构类似于正常汗腺的组织团块,而对照部位未观察到类似结构。S-100、NSE、Ⅷ－RAg和CD34在移植部位、对照部位、瘢痕组织以及正常皮肤均有表达,并且S-100、NSE、Ⅷ－RAg和CD34在移植部位再生汗腺组织中的分布与在正常皮肤汗腺组织中的分布极其相似。结论诱导骨髓间充质干细胞再生汗腺的组织中均有神经与血管分布,提示形成具有功能的汗腺组织可能受到新生神经的支配和新生血管的血液供应,骨髓间充质干细胞经诱导可以生成形态和功能较好的汗腺组织。     

人前列腺特异性抗原的原核表达及多克隆抗体制备

目的：建立人前列腺特异性抗原（prostate specific antigen,PSA）的可溶性大肠杆菌表达系统,获得高活性重组人PSA及多克隆抗体,为临床相关疾病的监测、诊断和治疗提供关键材料。方法：构建可溶性表达载体pET-S1-S2-PSA质粒,采用化学法将pET-S1-S2-PSA质粒转化大肠杆菌BL21（DE3）细胞,IPTG诱导BL21（DE3）细胞表达rPSA,阳离子交换层析纯化rPSA,经Western印迹鉴定后免疫大耳白兔制备PSA抗体,ELISA法检测抗体效价。结果与结论：构建了可溶性表达载体pET-S1-S2-PSA,获得了可溶性高表达rPSA的BL21（DE3）细胞株,并制备了可特异性结合天然PSA的抗体,其效价在1∶20000以上。     

人类白细胞抗原多态性与慢性肾功能衰竭的遗传易感性研究

目的：研究人类白细胞抗原（human leukocyte antigen,HLA）多态性与慢性肾功能衰竭（chronic renal failure,CRF）的遗传易感性。方法：采用聚合酶链反应．序列特异引物（PCR-SSP）技术,对2002—2007年间来我室配型的377例汉族慢性肾功能衰竭患者以及1212例正常无血缘关系汉族人群进行HLA-A／B／DRB1／DQB1基因分型,并对其在CRF患者及正常人群中的基因频率、单倍型频率以及相对危险度（RR）等进行统计学分析。结果：疾病组HLA-A＊02[RR（95％CI）：1．3598（1．2345,1．4978）]、DRBl＊04[RR（95％CI）：1．3651（1．1052,1．6862）]、DRB1＊12[RR（95％CI）：1．3162（1．0824,1．6006）]、DQB1＊0301[RR（95％CI）：1．3434（1．1745,1．5367）]以及DQB1＊0302[RR（95％CI）：1．5330（1．1136,2．1104）]可能是慢性肾功能衰竭的易感基因,而HLA-A＊11[RR（95％CI）：0．5782（0．4978,0．6849）]、B＊46[RR（95％CI）：0．6580（0．4930,0．8082）]、DQB1＊02[RR（95%CI）：0．7452（0．5961,0．9317）]以及DQBl＊05[RR（95%CI）：0．7742（0．6470,0．9264）]可能是慢性肾功能衰竭的保护性基因。DRB1＊11-DQB1＊0301[RR（95％CI）：1．5539（1．1896,2．0298）]、DRB1＊12-DQB1＊0301[RR（95％CI）：1．3315（1．0869,1．6311）]、A＊02-B＊15[RR（95％CI）：1．4654（1．0751,1．9973）]可能是慢性肾功能衰竭的易感单倍型型别。结论：慢性肾功能衰竭发生、发展与HLA基因型及其单倍型多态性有关,探讨该病与HLA多态性的易感性,对于研究CPF致病因素及治疗等具有一定意义。     

The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram

Between 10% and 25% of patients with newly diagnosed prostate cancer without bone metastases at the time of diagnosis will develop metastases during follow-up. To determine the value of clinical and biochemical parameters for assessment of prognosis at the time of diagnosis, a retrospective study was performed in 124 consecutive patients with newly diagnosed prostate cancer without bone metastases. The mean follow-up was 41 months, during which time 36 patients died and 15 patients developed metastases. Bone scans were classified from 0 (=normal) through 2 (=abnormal, but not typical for metastases) and were correlated with age, alkaline phosphatase (AP), prostate-specific antigen (PSA), tumour grade, T-stage and N-stage. In patients with a class 2 scan, additional roentgenograms and follow-up were used to exclude metastases at initial stage. All parameters, including therapy, were finally correlated with the development of metastases and survival. For survival 38 patients with proven metastases were used as controls. For all parameters tested, no statistically significant differences were found between the three bone scan classifications. The interval between diagnosis and the development of metastases ranged from 12 to 72 months. For the risk of development of metastases only PSA was found to be a significant correlate (P=0.0075). However, when tumour stages were clustered in limited disease (T0–2) and extensive disease (T3–4), the incidence of metastases was significantly higher in patients with extensive disease than in those with limited disease (P=0.0021). Finally, age, PSA and Anderson classification were found to be significant correlates of survival, but in stepwise analysis PSA was selected as the most prognostic variable (P<0.0001). In contrast with a typical pattern of metastases on bone scintigraphy, an abnormal scan (class 1 and 2) at the time of diagnosis is not a poor prognostic parameter of the risk of death. In conclusion, in patients with prostate cancer without bone metastases at the time of diagnosis, pretreatment PSA and tumour stage can be used for the assessment of risk of development of metastases during follow-up and survival. For this purpose, tumour stage should be clustered in limited and extensive disease. Received 14 April and in revised form 9 June 1997     

人抗HBsAg噬菌体抗体Fab段基因的序列分析及表达

对已建的噬菌体抗体库分离出来的人抗－ＨＢｓ克隆进行了序列分析和表达研究，发现４个克隆中３个克隆的重链和轻链完全相同，ＤＮＡ序列分析表明ＶＨ分别属于ＶＨ１亚群和Ⅱ亚群，其轻链ＶＬ分别属于ＶλⅡ亚群和ＶλⅠ亚群。构建了可溶性Ｆａｂ段表达载体，显示出在细菌中表达的Ｆａｂ段抗体与ＨＢｓＡｇ特异性结合，这说明所筛选出来的噬菌体抗体具有ＨＢdisplay status